Cargando…

Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients

Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy. There is no preferred treatment for recurrent ICC. We retrospectively reviewed our patients who underwent repeated operations for recurrent ICC...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Chun-Yi, Wang, Shang-Yu, Chan, Kun-Ming, Lee, Wei-Chen, Chen, Tse-Ching, Yeh, Ta-Sen, Jan, Yi-Yin, Yeh, Chun-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029635/
https://www.ncbi.nlm.nih.gov/pubmed/35455657
http://dx.doi.org/10.3390/jpm12040540
_version_ 1784691928355307520
author Tsai, Chun-Yi
Wang, Shang-Yu
Chan, Kun-Ming
Lee, Wei-Chen
Chen, Tse-Ching
Yeh, Ta-Sen
Jan, Yi-Yin
Yeh, Chun-Nan
author_facet Tsai, Chun-Yi
Wang, Shang-Yu
Chan, Kun-Ming
Lee, Wei-Chen
Chen, Tse-Ching
Yeh, Ta-Sen
Jan, Yi-Yin
Yeh, Chun-Nan
author_sort Tsai, Chun-Yi
collection PubMed
description Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy. There is no preferred treatment for recurrent ICC. We retrospectively reviewed our patients who underwent repeated operations for recurrent ICCs based on their different indications to appraise the outcomes. Methods: In all, 160 out of 216 patients with ICC (71.4%) experienced recurrence after curative resection from 1977 to 2014. The patterns of recurrence were categorized according to the locations and numbers of recurrent tumors. Results: Patients with merely intrahepatic recurrence (n = 38) had superior overall survival (OS) compared with those with beyond intrahepatic recurrence (p < 0.0001). Twenty-seven out of 160 patients (16.8%) underwent repeat hepatectomy or/with metastatectomy for recurrence and had superior OS when compared to the remaining 133 patients who received nonoperative treatment/palliation (85.6 months versus 20.9 months, p < 0.001). Furthermore, patients suitable for repeat hepatectomy in the intrahepatic recurrent group (n = 12) had superior post-recurrence overall survival (PROS) than the remaining 26 patients receiving nonoperative treatment (61.6 months versus 14.7 months, p < 0.05). Conclusion: Liver is the most commonly involved site of recurrent ICC. However, merely intrahepatic recurrence may have a favorable prognosis compared to recurrence involving other sites. Aggressive hepatectomy may provide a survival benefit in selected patients.
format Online
Article
Text
id pubmed-9029635
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90296352022-04-23 Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients Tsai, Chun-Yi Wang, Shang-Yu Chan, Kun-Ming Lee, Wei-Chen Chen, Tse-Ching Yeh, Ta-Sen Jan, Yi-Yin Yeh, Chun-Nan J Pers Med Article Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy. There is no preferred treatment for recurrent ICC. We retrospectively reviewed our patients who underwent repeated operations for recurrent ICCs based on their different indications to appraise the outcomes. Methods: In all, 160 out of 216 patients with ICC (71.4%) experienced recurrence after curative resection from 1977 to 2014. The patterns of recurrence were categorized according to the locations and numbers of recurrent tumors. Results: Patients with merely intrahepatic recurrence (n = 38) had superior overall survival (OS) compared with those with beyond intrahepatic recurrence (p < 0.0001). Twenty-seven out of 160 patients (16.8%) underwent repeat hepatectomy or/with metastatectomy for recurrence and had superior OS when compared to the remaining 133 patients who received nonoperative treatment/palliation (85.6 months versus 20.9 months, p < 0.001). Furthermore, patients suitable for repeat hepatectomy in the intrahepatic recurrent group (n = 12) had superior post-recurrence overall survival (PROS) than the remaining 26 patients receiving nonoperative treatment (61.6 months versus 14.7 months, p < 0.05). Conclusion: Liver is the most commonly involved site of recurrent ICC. However, merely intrahepatic recurrence may have a favorable prognosis compared to recurrence involving other sites. Aggressive hepatectomy may provide a survival benefit in selected patients. MDPI 2022-03-29 /pmc/articles/PMC9029635/ /pubmed/35455657 http://dx.doi.org/10.3390/jpm12040540 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tsai, Chun-Yi
Wang, Shang-Yu
Chan, Kun-Ming
Lee, Wei-Chen
Chen, Tse-Ching
Yeh, Ta-Sen
Jan, Yi-Yin
Yeh, Chun-Nan
Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
title Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
title_full Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
title_fullStr Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
title_full_unstemmed Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
title_short Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
title_sort hepatectomy or/with metastatectomy for recurrent intrahepatic cholangiocarcinoma: of promise for selected patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029635/
https://www.ncbi.nlm.nih.gov/pubmed/35455657
http://dx.doi.org/10.3390/jpm12040540
work_keys_str_mv AT tsaichunyi hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients
AT wangshangyu hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients
AT chankunming hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients
AT leeweichen hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients
AT chentseching hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients
AT yehtasen hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients
AT janyiyin hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients
AT yehchunnan hepatectomyorwithmetastatectomyforrecurrentintrahepaticcholangiocarcinomaofpromiseforselectedpatients